期刊文献+

541例女性晚期非小细胞肺癌患者的预后因素分析 被引量:5

Analysis of Prognostic Factors in 541 Female Patients with Advanced Non-small Cell Lung Cancer
下载PDF
导出
摘要 背景与目的随着女性肺癌发病率的攀升,其独特的临床和流行病学特征及良好预后引起了学界的关注。本研究通过回顾性分析女性晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的临床资料,探讨其预后相关因素。方法收集541例女性晚期NSCLC患者的临床资料,并随访至死亡。主要观察指标为总生存(overallsurvival,OS)。采用SPSS11.0统计软件进行生存分析。结果全组腺癌占80.2%(434/541),总体中位OS为15个月(95%CI:13.87-16.13),1年、2年、5年生存率分别为58.8%、23.7%和3.20%。单因素分析显示,临床分期、ECOG评分、体重下降、临床症状、血行转移和一线治疗后化疗方案数>1、一线化疗有效、曾接受靶向治疗或放疗均与中位OS明显相关(P值均<0.05)。治疗前体重下降、ECOG评分、靶向治疗及一线化疗有效为生存的独立预后因素(P值均<0.05)。结论女性晚期NSCLC患者的病理类型以腺癌为主,体重下降、ECOG评分、接受靶向治疗及一线化疗有效可能成为女性晚期NSCLC患者生存的独立预后指标。 Background and objective As there is a sharp increase in the incidence of lung cancer in women in recent years,it has brought broad concerns with its unique clinical and epidemiological characteristics and be er prognosis.e aim of this study is to analyze the clinical data of women with advanced non-small cell lung cancer(NSCLC) retrospectively to explore the prognostic factors.Methods Clinical data of 541 female patients with advanced NSCLC were collected and followed up till death.e primary endpoint is overall survival(OS) .SPSS 11.0 statistical analysis so ware was used for univariate and multivariate analysis.Results e mean age is 59 years(20 years-86 years) ,adenocarcinoma account for 80.2%(434/541) . The median OS was 15 months(95%CI:13.87-16.13) ,and 1,2,5-year survival rates were 58.8%,23.7%and 3.20%respectively.Univariate analysis showed that clinical stage,ECOG score,weight loss,clinical symptoms,liver/bone/brain metastasis and received more than one chemotherapy regimen,good response to the rst-line chemotherapy,EGFR-TKI targeted therapy and radiotherapy treatment were signi cantly correlated with the OS and survival rate(P0.05) .Combined with multivariate analysis,weight loss before treatment,ECOG score,received EGFR-TKI targeted therapy and response to rst-line chemotherapy were independent prognostic factor for survival(P0.05) .Conclusion ere is a higher percentage of adenocarcinoma in female NSCLC.Weight loss before treatment,ECOG score,EGFR-TKI targeted therapy and response to rst-line chemotherapy may become independent prognostic factors for survival of female patients with advanced NSCLC.
出处 《中国肺癌杂志》 CAS 2011年第3期245-250,共6页 Chinese Journal of Lung Cancer
关键词 肺肿瘤 女性 生存 预后 Lung neoplams Female Survival Prognosis
  • 相关文献

参考文献6

  • 1Guillermo PJ, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(S676): 1497-1500. 被引量:1
  • 2FuJB, Kau TY, Severson RK, et al. Lung cancer in women:analysis of the national Surveillance, Epidemiology, and End Results database. Chest, 2005,127(3): 768-777. 被引量:1
  • 3Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20S61 cases. Ann Oncol, 2002, 13(7): 1087-1093. 被引量:1
  • 4Wakelee HA, Wang W, Shiller JH, et al. Survival deifferences by sex for patients with advanced non-small-cell lung cancer on Eastern Cooperative Oncology Group Trial 1594.J Thorac Oncol, 2006, 1 (S): 441-446. 被引量:1
  • 5O'Connel, Kris MG, Gralla RJ, et al. Frequency and prognostic importance ofpretreatment clinical characteristics in patients with advanced non-smallcell lung cancer treated with combination chemotherapy.J Clin Oncol, 1986, 4(11): 1604-1614. 被引量:1
  • 6杨功焕著..中国人群死亡及其危险因素流行水平、趋势和分布[M].北京:中国协和医科大学出版社,2005:351.

同被引文献38

  • 1陈衍智,李占东,高非,张莹,孙红,李萍萍.Effects of Combined Chinese Drugs and Chemotherapy in Treating Advanced Non-small Cell Lung Cancer[J].Chinese Journal of Integrative Medicine,2009,15(6):415-419. 被引量:18
  • 2陈乾坤,丁嘉安,高文,朱余明.Ⅲ期非小细胞肺癌纵隔淋巴结跳跃式转移的临床意义[J].中华结核和呼吸杂志,2005,28(7):472-474. 被引量:6
  • 3Ganti AK,Weir AB,Hurria A. Treatment of non-small cell lung cncer in the older patient[J].J Natl Compr Canc Netw,2012,(2):230-239. 被引量:1
  • 4Fang G,Brooks JM,Chrischilles EA. Apples and oranges?Interpretations of risk adjustment and instrumental varia-ble estimates of intended treatment effects using observa-tional data[J].{H}American Journal of Epidemiology,2012,(1):60-65. 被引量:1
  • 5Berghmans T,Pasleau F,Paesmans M. Surrogate mark-ers predicting overall survival for lung cancer:ELCWP recom-mendations[J].{H}European Respiratory Journal,2012,(1):9-28. 被引量:1
  • 6Maniwa T,Okumura T,Isaka M. Recurrence of me-diastinal node cancer after lobe-specific systematic nodal dissection for non-small-cell lung cancer[J].Eur J Cardio-thor Surg,2013,(1):e59-e64. 被引量:1
  • 7Darling GE,Allen MS,Decker PA. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the pa-tient with N0 or N1(less than hilar) non-small cell carci-noma:Results of the American College of Surgery Oncol-ogy Group Z0030 Trial[J].{H}Journal of Thoracic and Cardiovascular Surgery,2011,(3):662-670. 被引量:1
  • 8Chikako Kiyohara,Yoshiyuki Ohno.Sex differences in lung cancer susceptibility: A review[J].Gender Medicine.2010(5) 被引量:1
  • 9Li-Han Hsu,Nei-Min Chu,Chia-Chuan Liu,Stella Y.C. Tsai,Dong-Ling You,Jen-Sheng Ko,Mei-Chun Lu,An-Chen Feng.Sex-associated differences in non-small cell lung cancer in the new era: Is gender an independent prognostic factor?[J].Lung Cancer.2009(2) 被引量:1
  • 10Hisao Asamura,Tomoyuki Goya,Yoshihiko Koshiishi,Yasunori Sohara,Kenji Eguchi,Masaki Mori,Yohichi Nakanishi,Ryosuke Tsuchiya,Kaoru Shimokata,Hiroshi Inoue,Toshihiro Nukiwa,Etsuo Miyaoka.A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers[J].Journal of Thoracic Oncology.2008(1) 被引量:1

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部